Phreesia (NYSE:PHR) Stock Rating Lowered by Barclays

Phreesia (NYSE:PHR) was downgraded by research analysts at Barclays from a “strong-buy” rating to a “hold” rating in a report released on Thursday,Zacks.com reports.

PHR has been the topic of a number of other research reports. Truist Financial restated a “hold” rating and issued a $11.00 price target (down from $24.00) on shares of Phreesia in a research report on Tuesday, March 31st. Robert W. Baird restated a “neutral” rating and issued a $10.00 price target (down from $25.00) on shares of Phreesia in a research report on Tuesday, March 31st. Canaccord Genuity Group decreased their price target on Phreesia from $33.00 to $22.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. JPMorgan Chase & Co. restated a “neutral” rating and issued a $16.00 price target (down from $24.00) on shares of Phreesia in a research report on Tuesday, March 31st. Finally, Wall Street Zen cut Phreesia from a “buy” rating to a “hold” rating in a research report on Saturday, April 4th. Eleven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Phreesia currently has an average rating of “Moderate Buy” and an average target price of $20.00.

Phreesia Stock Up 0.1%

PHR opened at $8.78 on Thursday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.53 and a current ratio of 1.53. Phreesia has a fifty-two week low of $7.77 and a fifty-two week high of $32.76. The company has a market capitalization of $533.29 million, a P/E ratio of 292.57 and a beta of 0.89. The stock has a fifty day moving average of $9.94 and a 200-day moving average of $14.53.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Monday, March 30th. The company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.05). Phreesia had a return on equity of 3.23% and a net margin of 0.48%.The company had revenue of $127.07 million during the quarter, compared to the consensus estimate of $126.75 million. During the same quarter in the previous year, the business posted ($0.11) EPS. The firm’s revenue for the quarter was up 15.9% on a year-over-year basis. On average, equities analysts expect that Phreesia will post 0.28 EPS for the current year.

Insiders Place Their Bets

In other Phreesia news, General Counsel Allison C. Hoffman sold 14,483 shares of Phreesia stock in a transaction dated Friday, April 10th. The stock was sold at an average price of $8.07, for a total value of $116,877.81. Following the transaction, the general counsel owned 163,485 shares in the company, valued at $1,319,323.95. The trade was a 8.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Balaji Gandhi sold 3,829 shares of Phreesia stock in a transaction dated Wednesday, March 25th. The shares were sold at an average price of $11.26, for a total value of $43,114.54. Following the completion of the transaction, the chief financial officer owned 146,740 shares in the company, valued at approximately $1,652,292.40. This represents a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 50,493 shares of company stock worth $461,983. Insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Raymond James Financial Inc. grew its position in Phreesia by 2.7% in the second quarter. Raymond James Financial Inc. now owns 14,049 shares of the company’s stock valued at $400,000 after acquiring an additional 375 shares during the last quarter. Alliancebernstein L.P. grew its position in Phreesia by 1.3% in the third quarter. Alliancebernstein L.P. now owns 62,712 shares of the company’s stock valued at $1,475,000 after acquiring an additional 812 shares during the last quarter. Van ECK Associates Corp grew its position in Phreesia by 78.7% in the fourth quarter. Van ECK Associates Corp now owns 2,502 shares of the company’s stock valued at $42,000 after acquiring an additional 1,102 shares during the last quarter. Arizona State Retirement System grew its position in Phreesia by 8.1% in the third quarter. Arizona State Retirement System now owns 17,608 shares of the company’s stock valued at $414,000 after acquiring an additional 1,313 shares during the last quarter. Finally, Federated Hermes Inc. bought a new position in Phreesia in the third quarter valued at about $32,000. Institutional investors own 92.10% of the company’s stock.

Phreesia News Summary

Here are the key news stories impacting Phreesia this week:

• Negative Sentiment: Multiple law firms, including Rosen Law Firm, Faruqi & Faruqi, Pomerantz, Bragar Eagel & Squire, Gross Law Firm, Robbins LLP, and Gainey McKenna & Egleston, announced or promoted class-action lawsuits against Phreesia, alleging potential securities fraud tied to the period from May 8, 2025 through March 30, 2026. Article Title
• Negative Sentiment: The lawsuits and related investor alerts may increase legal costs, management distraction, and uncertainty around prior disclosures, which can weigh on investor sentiment toward the stock. Article Title
• Neutral Sentiment: Phreesia’s latest quarterly results were mixed: revenue came in slightly above expectations, but EPS missed consensus, which may still be influencing how investors view the company’s fundamentals.
• Neutral Sentiment: Despite the recent news flow, analysts previously remained constructive overall, with several Buy/Outperform ratings and a median price target above the current share price, suggesting some longer-term optimism remains.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.